Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (23)

I-016Giammarco Baiardi

population pharmacokinetics and dose rationale for deferasirox in the treatment of iron overload in paediatric patients undergoing hematopoietic stem cell transplantation

Wednesday 10:20-11:50

I-045Nils Bundgaard

Characterization of the population dose-exposure-efficacy relationships of vamorolone, a synthetic corticosteroid drug in the treatment of Duchenne Muscular Dystrophy (DMD)

Wednesday 10:20-11:50

I-046Andrew Butler

Predicting the effect of postpartum changes in breastmilk composition on the partitioning of anti-malarial medications

Wednesday 10:20-11:50

I-070Craig Comisar

Population pharmacokinetic modeling to support dose selection of zavegepant nasal spray in pediatrics.

Wednesday 10:20-11:50

I-075Liu Dan

Population pharmacokinetics modeling of selpercatinib and simulation to support posology in paediatric and adolescent patients

Wednesday 10:20-11:50

I-086Laure Deyme

Population pharmacokinetic analysis of eliglustat in pediatric patients with Gaucher disease

Wednesday 10:20-11:50

I-115Gastón García Orueta

Population pharmacokinetics of teicoplanin in critically ill children undergoing continuous kindey replacement therapy

Wednesday 10:20-11:50

II-012Katharina Martha Götz

The dose-response relationship of rituximab in pediatric patients after allogeneic hematopoietic stem cell transplantation – Model-informed evidence generation for a real-world problem

Wednesday 15:20-16:50

II-022Andrea Guzmán

Potential of Tacrolimus CYP3A5 genotyping to predict phenotype (C0/Dose/Weight ratio) and applicability of PBPK modelling to improve dosing strategies in paediatric kidney transplant recipients

Wednesday 15:20-16:50

II-030Huan He

Is the model predictive performance with von Willebrand factor superior to others? An external evaluation of population pharmacokinetic models for FVIII concentrate BAY 81-8973 in pediatric patients with haemophilia A

Wednesday 15:20-16:50

II-091Sebastiano Lava

Study design optimization in paediatric rare diseases: a case study on empagliflozin in paediatric heart failure

Wednesday 15:20-16:50

II-108CHENYAO LIU

Population Pharmacokinetic of ketamine and norketamine in pediatric subjects during analgosedation

Wednesday 15:20-16:50

III-018Andres Mazariegos Herrera

Weight-band based simplification of oral allometric miltefosine dosing in pediatric patients with visceral leishmaniasis in Eastern Africa

Thursday 09:50-11:20

III-057Zinnia Parra-Guillen

Optimal study design for pharmacokinetic modeling of teicoplanin in critically ill children, including those undergoing Continuous Renal Replacement Therapy

Thursday 09:50-11:20

III-077Laure-Hélène Préta

Antidepressants transplacental transfer modeling using ex vivo perfusion of isolated human placenta cotyledon

Thursday 09:50-11:20

IV-001Gianluca Selvaggio

Physiologically based pharmacokinetic modelling to support design of microarray patches delivering antiretroviral drugs to HIV positive children

Thursday 15:00-16:30

IV-046Lufina Tsirizani

Population pharmacokinetics of ritonavir administered to boost lopinavir, atazanavir, or darunavir in children with HIV in Africa.

Thursday 15:00-16:30

IV-055Jennie van Dyk

Oral amoxicillin/clavulanate in paediatric patients with severe community acquired pneumonia: a popPK analysis from the PediCAP trial

Thursday 15:00-16:30

IV-059Anne van Rongen

The impact of being born Small for Gestational Age (SGA) on the clearance of vancomycin versus morphine and midazolam

Thursday 15:00-16:30

IV-093Jen-Hao (Eric) Wu

Clinical trial design evaluation in pediatric oncology: Phase I dose finding trial design optimization exemplified by brigatinib (ITCC-098)

Thursday 15:00-16:30

IV-095Maria Xiberras

External Validation of a Population Pharmacokinetic Model for Morphine and its Metabolites in Children under 3 Years who Underwent Cardiothoracic Surgery

Thursday 15:00-16:30

IV-111Qiaolin Zhao

Population pharmacokinetic analysis for pediatric patients with inflammatory bowel disease receiving infliximab

Thursday 15:00-16:30

IV-115Yuanxi Zou

Pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistance tuberculosis

Thursday 15:00-16:30